Joshua Fitch, Senior Editor

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Findings from a newly-published study revealed that newborn metabolic profiles may identify infants at an increased risk for SIDS shortly after birth.

Linda DiMeglio, MD, MPH, joined us to discuss the “Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes."

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to talk PGHD and the role of the pediatrician when it comes to treatment.

Alan Percy, MD, discusses where the general provider comes in when treating Rett syndrome and prescribing trofinetide (Daybue).

Investigators concluded that findings suggest the need for improved public health messaging regarding fish intake guidelines for pregnant persons.

In this last episode, our panel discusses this patient population and the challenges around keeping them in the continuum of care.

Availability for the type 1 allergic reactions treatment approved by the FDA in August is expected later this month.

Alan Percy, MD, discussed what the FDA approval of trofinetide (Daybue) has meant to patients with Rett syndrome aged 2 years and older.

Screen time before bed did not impair sleep in children, but in-bed use demonstrated delayed sleep onset and reduced total sleep time.

Following the final ruling, requirements will be implemented beginning September 30, 2024.

The investigational MEK inhibitor has been assigned a Prescription Drug User Fee Act (PDUFA) date of February 28, 2025.

In this episode, clinicians discuss challenges associated with these topics and offer some insights on them.

Efficacy of roflumilast cream 0.05% improved over time among children aged 2 to 5 years with mild to moderate atopic dermatitis.

IIV3s, RIV3, and LAIV3 influenza vaccines are expected to be available.

The report links high fluoride exposure to lower IQ in children, though the American Fluoridation Society noted the high levels are more than double what is used for water fluoridation in North America.

Following the FDA's acceptance of the NDA, a PDUFA date of December 26, 2024 has been set for setmelanotide in patients as young as 2 years of age.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A CDC report reviews HPV vaccination trends in US Pacific Islands, revealing mixed progress towards the 2030 goal of 90% completion among girls by age 15.

The federal agency advised manufacturers in June that 2024-2025 COVID-19 vaccines should be monovalent JN.1, with the preferred lineage being the KP.2 strain.

Healthcare providers should maintain heightened suspicion of parvovirus B19 in individuals presenting with symptoms, particularly those at high risk.

Lynn Malec, MD, joins Contemporary Pediatrics once again for a discussion of the hemophilia A space and how pediatric health care providers fit into care.

Expert discussion of several topics including diagnosis, clinical management in older adults, multidrug resistance, and long-acting injectables and PrEP.

The FDA approved anacaulase-bcdb for pediatric use, allowing its application for eschar removal in deep thermal burns for ages newborn to 18 years.

The USPSTF statement aligns with the 2015 recommendation on insufficient evidence for pregnancy iron deficiency screening or supplementation.

Findings show that that feeding mode is by far the most defining factor for microbial composition," wrote the study authors.

A JAMA Pediatrics study found 37% of adolescents with gender dysphoria began hormone therapy within 2 years, highlighting barriers and inequities in care.

An interactive text message program boosted vaping cessation rates by 35% among adolescents compared to a control group, a JAMA study found.

The approval is indicated for adult and pediatric patients who weigh at least 88 lbs (40 kg).